Sangivamycin is highly effective against SARS-CoV-2 in vitro and has favorable drug properties

Document Details

Document Type
Pub Defense Publication
Publication Date
Jan 11, 2022
Source ID
10.1172/jci.insight.153165

Entities

People

  • Brett P. Eaton
  • Charles O Smith
  • Elena N. Postnikova
  • Gregory A. Kocher
  • Harold C. Smith
  • Huanying Zhou
  • Janie Liang
  • Jens H. Kuhn
  • Michael J. Murphy
  • Ryan P. Bennett
  • Shuiqing Yu
  • Yíngyún Caì

Organizations

  • National Institutes of Health